|
|
|
|
|
11.08.25 - 22:15
|
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
|
|
|
Announced design of Embolden™ registrational clinical trial of NGN-401 gene therapy for Rett syndrome; trial initiation activities underway
Completed dosing in Phase 1/2 NGN-401 trial, and remains on track to report updated clinical efficacy and safety data in the second half of 2025
Cash runway into early 2028NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates.
“In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement from the U.S. FDA on the key elements of the Embolden™ registrational trial, in which we have already begun initiation activities,” stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neur...
|
|
|
08.08.25 - 22:06
|
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 27,480 shares of the Company's common stock to seven new employees (the “Inducement Grants”) on August 6, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of th...
|
|
|
03.07.25 - 22:06
|
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,290 shares of the Company's common stock to two new employees (the “Inducement Grants”) on July 3, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the ves...
|
|
|
06.06.25 - 22:06
|
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the “Inducement Grants”) on June 5, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the v...
|
|
|
|
|
16.05.25 - 13:06
|
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV (Business Wire)
|
|
|
Oral presentation at ASGCT Annual Meeting to describe algorithm to monitor, detect and treat HLH, which can be adopted for AAV gene therapy
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH) that has been associated with systemic exposure to high doses of adeno-associated virus (AAV) gene therapy (>1E14 vg/kg).
The 1E15 vg dose level Neurogene is moving forward in its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome translates into the E13 vg/kg range, and the Company is not aware of any case of HLH ever being reported at this dose level in AAV gene therapy.
“We appreciate the opportunity that ...
|
|
|
|
|
09.05.25 - 13:36
|
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
|
|
|
On track to provide registrational trial plan update for NGN-401 gene therapy for Rett syndrome in the first half of 2025
Continues to plan to provide clinical data update from ongoing NGN-401 Phase 1/2 trial in the second half of 2025
Cash runway into the second half of 2027
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates.
“We have made significant progress in planning for our future registrational trial with NGN-401 gene therapy for Rett syndrome and expect to provide an update on our plans during the first half of this year,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. “As we work to finalize our proposed trial design to differentiate and position the product candidate as potentially best-in-class for future commercialization...
|
|
|
|
|
24.03.25 - 21:12
|
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates (Business Wire)
|
|
|
Remains on track to provide regulatory update on registrational trial plans with NGN-401 for Rett syndrome in the first half of 2025
Continues to expect to share additional interim clinical data from NGN-401 Phase 1/2 trial in the second half of 2025
Received PRIME designation for NGN-401 from the European Medicines Agency
Cash runway into the second half of 2027
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates.
“We believe 2024 was a year of significant progress for our NGN-401 Phase 1/2 trial in Rett syndrome, as we reported encouraging interim efficacy data and NGN-401 was generally well-tolerated at the 1E15 vg dose in a pediatric cohort,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. “We remain on track to provi...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
